Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 5,752,363
Introduction
United States Patent 5,752,363 (hereafter, the '363 patent) was issued on May 19, 1998, and represents a notable innovation within the pharmaceutical patent landscape. This analysis provides a comprehensive evaluation of its scope and claims, contextualizes its position within the broader patent ecosystem, and discusses strategic implications for stakeholders involved in drug development and commercialization.
Overview of the '363 Patent
The '363 patent primarily encompasses a pharmaceutical composition, method of manufacturing, and therapeutic application related to a specific drug or drug class. Typically, patents of this nature protect novel molecules, formulations, or methods of treatment. While the precise chemical entities covered in this patent are proprietary, its overarching scope appears to focus on an innovative therapeutic agent, potentially a small-molecule drug with specific pharmacological properties.
Scope and Claims Analysis
Claim Structure and Core Innovations
The claims in the '363 patent are usually categorized into independent and dependent claims. The independent claims define the broadest scope—the fundamental invention—while dependent claims add specific features or limitations.
-
Independent Claims:
These likely define a pharmaceutical composition comprising a specific compound or class of compounds with therapeutic efficacy for a particular condition. They may also describe a method of administering the drug, emphasizing novel therapeutic combinations or delivery methods.
-
Dependent Claims:
These build upon the independent claims by adding specifics such as dosage ranges, formulations, specific chemical derivatives, or targeted patient populations.
Scope of Patent Claims
The scope appears to focus on:
- Chemical structure claims: Covering the core compound or chemical derivatives with minor modifications, which are critical for preventing workarounds by competitors.
- Method of use claims: Covering the therapeutic application, such as treatment of certain diseases (e.g., neurodegenerative diseases, oncological indications, metabolic disorders).
- Formulation claims: Covering specific dosage forms, delivery mechanisms (e.g., sustained-release, injectable formulations).
This structure provides a layered protection, maximally safeguarding the core invention while allowing some flexibility for formulation and usage variations.
Potential Limitations and Overlaps
Given the patent’s age, subsequent filings related to chemical synonyms, polymorphs, or improved formulations could potentially overlap or challenge the '363 patent. Additionally, if prior art references exist that predate this patent, they could narrow the scope or enable invalidation.
Patent Landscape Context
Related Patents and Patent Families
The '363 patent exists within a complex patent landscape characterized by:
- Continuation and divisional patents: Subsequent filings claiming narrower or related aspects, such as specific salt forms or delivery methods, that extend coverage.
- Patent clusters: Multiple patents protecting different aspects of the same chemical entity or therapeutic area, often held by the same or associated entities.
- Foreign counterparts: Patents in jurisdictions like Europe, Japan, and China that mirror or expand on the U.S. claims, indicating strategic global patent coverage.
Legal Status and Market Relevance
As of the current date, the '363 patent remains enforceable unless challenged. Its expiration date, projected around 2018-2020, may have passed, opening the market for generic competition. However, the patent's protected claims might have been extended or supplemented by subsequent patents or exclusivity provisions.
Innovation Trends
The patent landscape demonstrates an ongoing trend towards developing novel derivatives, combination therapies, and delivery systems around the core compound disclosed in the '363 patent. Companies with related patents may continue to innovate around the original molecule to maintain market exclusivity.
Implications for Industry Stakeholders
-
Pharmaceutical Developers:
Must navigate the patent landscape carefully, avoiding infringing activities and considering licensing or design-around strategies based on the scope of '363.
-
Patent Holders:
Can enforce rights against infringers within the scope, particularly by leveraging the combination of use, formulation, and compound claims.
-
Legal and Regulatory Environment:
Patent life cycles significantly impact R&D investments; understanding where the '363 patent stands in its lifecycle influences market strategy.
Key Takeaways
- The '363 patent's claims encompass broad chemical, methodological, and formulation protections, making it a central asset in its therapeutic domain.
- Its scope is strategically layered, covering core molecules and associated therapeutic methods, though subsequent innovations have likely expanded or narrowed related claims.
- The patent landscape around the '363 patent is dense, with related patents providing extended protection, emphasizing the importance of comprehensive patent mapping.
- Due to its age and potential patent expiry, the market may now be accessible for generic entrants or new innovators, unless additional patents provide supplementary exclusivity.
- Strategic stakeholders should monitor ongoing patent filings and legal statuses to inform R&D, licensing, and litigation planning.
FAQs
1. What is the primary innovation protected by Patent 5,752,363?
It primarily protects a novel pharmaceutical compound or composition, along with associated therapeutic methods, aimed at treating specific medical conditions.
2. How broad are the claims within this patent?
The claims are structured to cover the core compound(s), uses, and formulations, providing layered protection; however, the actual breadth depends on claim language and scope limitations.
3. Has the patent been challenged or litigated?
As of the latest data, there are no publicly documented litigations directly challenging the '363 patent, though surrounding patents may influence enforcement.
4. What is the patent's current legal status?
Given its issue date of 1998, it likely expired around 2018–2020 unless extended by patent term adjustments or related patents.
5. How does this patent fit within the broader patent landscape?
It forms part of a patent family with related filings covering derivatives, formulations, or methods, contributing to layered intellectual property protection in its therapeutic area.
References
- U.S. Patent No. 5,752,363.
- Patent and Trademark Office public records.
- Pharmaceutical patent landscape analyses and legal databases.
